BPG is committed to discovery and dissemination of knowledge
Featured Articles
8/26/2019 8:12:04 AM | Browse: 991 | Download: 2008
Publication Name World Journal of Clinical Cases
Manuscript ID 48171
Country Egypt
Received
2019-04-10 01:24
Peer-Review Started
2019-04-10 02:28
First Decision by Editorial Office Director
2019-05-09 15:18
Return for Revision
2019-06-03 09:17
Revised
2019-06-13 14:33
Publication Fee Transferred
Second Decision by Editor
2019-06-25 00:59
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2019-07-03 16:52
Articles in Press
2019-07-03 16:52
Edit the Manuscript by Language Editor
Typeset the Manuscript
2019-08-23 05:17
Publish the Manuscript Online
2019-08-26 02:56
ISSN 2307-8960 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Prospective Study
Article Title Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy
Manuscript Source Invited Manuscript
All Author List Mortada HF El-Shabrawi, Laila M Sherief, Mostafa Yakoot, Naglaa M Kamal, Mohamed A Almalky, Manal M AbdElgawad, Aml A Mahfouz, Sherine Helmy, Enas Mohamed Kamal, Dina Attia and Hisham R El-Khayat
Funding Agency and Grant Number
Corresponding Author Mostafa Yakoot, MD, Chairman, Chief Doctor, Internal medicine, Pediatrics and Hepatology, Green Clinic and Research Center, Alexandria University, 27 Green Street, Alexandria 21121, Egypt, Egypt. yakoot@yahoo.com
Key Words Chronic hepatitis C; Survivors of childhood cancer; Sofosbuvir; Daclatasvir; Efficacy;
Core Tip Dual Sofosbuvir/Daclatasvir (SOF/DCV) treatment was found to be as effective in the treatment of chronic hepatitis C virus (HCV) in survivors of childhood hematologic malignancy as in others with no history of malignancy. No relapses detected during study for the original malignant disease or the HCV infection. The results of this study could be assuring that the treatment of chronic HCV infection with direct-acting antivirals (DAAs) might not adversely affect the state of remission of survivors of hematologic malignancy in pediatric age groups; though larger studies with different DAAs and longer follow up are needed to confirm.
Publish Date 2019-08-26 02:56
Citation El-Shabrawi MH, Sherief LM, Yakoot M, Kamal NM, Almalky MA, AbdElgawad MM, Mahfouz AA, Helmy S, Kamal EM, Attia D, El-Khayat HR. Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy. World J Clin Cases 2019; 7(16): 2247-2255
URL https://www.wjgnet.com/2307-8960/full/v7/i16/ 2247.htm
DOI https://dx.doi.org/10.12998/wjcc.v7.i16.2247
Full Article (PDF) WJCC-7-2247.pdf
Full Article (Word) WJCC-7-2247.docx